Kenneth Galbraith

ZYME

Kenneth Galbraith serves as director, officer: Chair & CEO at Zymeworks Inc. (ZYME). This page tracks their complete SEC Form 4 insider trading history including stock purchases and sales.

Total Buys

0 trades

$0.00

Total Sells

5 trades

$6.50M

Net Position

Net Seller

$6.50M

Companies Traded

ZYME

Active Period

Jan 2024 – Jan 2026

5 total trades

Most Recent

Sell ZYME

Jan 12, 2026 · $1.38M

Kenneth Galbraith's Insider Trading at Zymeworks Inc. (ZYME)

Buys

0 · $0.00

Sells

5 · $6.50M

Total Shares Bought

Total Shares Sold

298,257

ZYME Price Chart

Loading chart...

Date	Type	Shares	Avg Price	Value	Shares After
Jan 12, 2026	Sell	60,848	$22.67	$1.38M	226,842
Jan 5, 2026	Sell	108,686	$25.10	$2.73M	193,266
Dec 22, 2025	Sell	47,528	$27.02	$1.28M	0
Jan 6, 2025	Sell	57,291	$14.92	$855.0K	80,803
Jan 8, 2024	Sell	23,904	$10.79	$257.8K	29,468

Related Insiders

Mark Hollywood

officer: EVP & Chief Operating Officer

ZYMESell · Jan 13, 2026

Paul Andrew Moore

officer: Chief Scientific Officer

ZYMESell · Jan 12, 2026

Jeffrey T L Smith

officer: EVP & Chief Medical Officer

ZYMESell · Jan 12, 2026

Explore More Insider Trading Data

ZYME Insider Trading Activity

View all insider trades at Zymeworks Inc.

Healthcare Sector Insider Trades

See insider activity across healthcare stocks

Latest Insider Buys

Most recent insider purchases across all stocks

CEO Stock Purchases

Track CEO buying activity